SCM
MRSN

Sterling Capital Management’s Mersana Therapeutics MRSN Stock Holding History

Sterling Capital Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-38
Closed -$325 – 3343
2025
Q1 		$325 Sell
38
-38
-50% -$586 ﹤0.01% 3025
2024
Q4 		$2.72K Buy
76
+67
+744% +$3.47K ﹤0.01% 2691
2024
Q3 		$442 Buy
+9
New +$397 ﹤0.01% 2924

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Sterling Capital Management's MRSN Position: Q2 2025 in Review

Sterling Capital Management sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 38 shares — an estimated $325 sold.

Sterling Capital Management first reported a position in MRSN in Q3 2024 and held it in 3 quarters. The position peaked at $2.72K in Q4 2024. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • Sterling Capital Management reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 38 Mersana Therapeutics shares in Q2 2025, an estimated $325.
  • Sterling Capital Management first reported a position in Mersana Therapeutics in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's Mersana Therapeutics position peaked at $2.72K in Q4 2024.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.